Clinical Trials · NCT05516966
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Enrollment
- 64
- Start date
- Oct 2022
- Locations
- 1 site, China
- Primary endpoint
- Incidence of Adverse Events (Safety and Tolerability)